Value through Innovation

main navigation

jump to content to meta navigation
Headillu

page content

jump to main navigation to meta navigation

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
26.07.2010 European Committee for Medicinal Products for Human Use (CHMP) adopts Positive Opinion for TWYNSTA®, Boehringer Ingelheim’s new single pill combination hypertension treatment - For non-US and non-UK Healthcare Media
22.07.2010 VERxVE study demonstrates efficacy and safety of 400mg once daily nevirapine (Viramune®) extended release (NVP XR) formulation
08.07.2010 First PCV-2 / Mycoplasma hyopneumoniae vaccine combination registered in the European Union
06.07.2010 Fekrije Selimi wins Boehringer Ingelheim’s FENS Award 2010 for Exceptional Research in Neuroscience
06.07.2010 Metacam® for pigs now also available as oral suspension
28.06.2010 Boehringer Ingelheim launches PCV2 vaccine in Russia
26.06.2010 Boehringer Ingelheim announces results of phase III data showing that linagliptin significantly lowered blood glucose with an excellent safety and tolerability profile - For non-US healthcare media only
18.06.2010 Boehringer Ingelheim receives European approval for two new strengths for the once daily tablet formulation of Mirapexin®/Sifrol® prolonged-release for the treatment of Parkinson’ s disease - For non-US Healthcare Media
18.06.2010 Boehringer Ingelheim Comments on June 18th FDA Advisory Committee Meeting - For NON-US and NON-UK Media Only
14.06.2010 Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients and strongly disagrees with the publication of Sipahi et al in Lancet Oncology June 2010 - For Medical Media Only
11.06.2010 Dabigatran etexilate as effective and safe as enoxaparin in preventing venous thromboembolism (VTE) after total hip replacement surgery and significantly reduced the combined endpoint of major VTE and VTE-related death - For NON-US Healthcare Media Only
21.05.2010 Boehringer Ingelheim’s lead investigational oncology compound BIBW 2992 demonstrates potential as a next generation treatment for non-small cell lung cancer and head-and-neck cancer
19.05.2010 Women with hypoactive sexual desire disorder (HSDD) report that flibanserin increased their sexual desire and reduced associated distress - For medical media, outside the US only
06.05.2010 World’s No. 1 selling laxative - New study results on Dulcolax® confirm efficacy and safety
05.05.2010 Boehringer Ingelheim and Micromet announce global collaboration for multiple myeloma BiTE antibody
20.04.2010 Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in R&D / market launch of five innovative medicines planned
15.04.2010 Topping-out ceremony at Boehringer Ingelheim – production site for innovative anticoagulant is being expanded
14.04.2010 Boehringer Ingelheim announces successful completion of a tender offer to acquire outstanding shares in SSP Co., Ltd.
back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
back to top

Contact

Boehringer Ingelheim GmbH

Corporate Headquarters
Binger Str. 173
55216 Ingelheim
Germany


Phone +49 / 6132 / 77 0
Fax +49 / 6132 / 72 0

media contacts

RSS feeds allow you to receive latest news and information about Boehringer Ingelheim.

subscribe to RSS Feed